Ref: The Journal of Applied Neurosciences, 2005, vol.2005-1.14
Aluminum is frequently mentioned as a potential risk factor of Alzheimer’s disease (AD). There is an important literature related to this problem, with pros and cons, and this is still a matter of debate. Our goal was to address the problem directly and quantify this metal in the patient’s brain from a prospective study that was fully characterized at the clinical, neuropathological and biochemical levels. In particular, the two degenerating processes that characterize AD were staged with a reliable and simple method, based on the quantification of pathological tau proteins and aggregated Abeta x-42 species. Moreover, we split the group of non-demented patients into two subgroups according to the absence or presence of Abeta deposits, corresponding to “controls” and incipient (prodromal) AD, respectively. Aluminum as well as other metals were quantified by two methods that are sensitive and specific: inductively coupled plasma (ICP) mass spectrometry and ICP- absorption emission spectrometry. The frontal cortices of 49 cases were analyzed. Results show that the levels of aluminum in the brain of controls are lower than expected, less than 1 microgram per gram of tissue, and are not significantly increased for degenerative disorders, including Alzheimer’s disease.
Copyright ADNA ; email@example.com for reproduction